Generic Name: pexidartinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Daiichi Sankyo

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Turalio is a kinase inhibitor approved for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) that is associated with severe functional limitations and cannot be treated with surgery.

General Info

Tenosynovial giant cell tumor is a rare tumor that affects the tissue covering the surfaces of joints and tendon sheaths. Though rarely malignant, it can damage joints and tendons. Turalio has multiple targets including that play a role in cell proliferation, including CSF1R, KIT and FLT3.

The Phase III ENLIVEN trial showed that it shrank tumors in 38% of patients, compared with 0% of placebo recipients. Turalio was approved in August 2019.


Dosing Info:

Turalio is taken as a capsule twice daily on an empty stomach.

Side Effects

Common side effects include eye swelling, rash, altered taste sensation (dysgeusia) and laboratory abnormalities including increased lactate dehydrogenase, alkaline phosphatase and cholesterol levels, elevated ALT and AST liver enzyme levels, and a decrease in neutrophils and lymphocytes. The Turalio label includes a warning about the risk of severe liver toxicity. The drug may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: August 6, 2019